189 results about "Phosphatidic acid" patented technology

Compositions and methods for making and using anti-LPA agents, for example, monoclonal antibodies, are described. Variable domain and complementarity determining region amino acid sequences of several monoclonal antibodies against LPA are disclosed, as is a consensus anti-LPA monoclonal antibody variable domain sequence.

Described herein is an isolated polynucleotide encoding an LPA receptor. Also described is a recombinant DNA molecule comprising a nucleic acid encoding an LPA receptor and expression controlling elements linked therewith, as well as the use of nucleic acid coding for an LPA receptor for expression to obtain a functional receptor protein and for further gene cloning to identify structurally related receptor proteins. Also described herein is LPA receptor as a product of recombinant production in a cellular host. Described is a method of utilizing the LPA receptor in a chemical screening program to identify LPA receptor ligands. The invention further describes antibodies directed to the LPA receptor for use for example in diagnosis of conditions wherein the levels of LPA are altered.

Methods are provided for increasing neuronal differentiation of neuronal stem cells using antibodies that bind lysophosphatidic acid (LPA). Particularly preferred antibodies to LPA are monoclonal antibodies, including humanized monoclonal antibodies to LPA. Such antibodies, and derivatives and variants thereof, can be used in increasing neuronal differentiation, and in treatment and / or prevention of injuries, diseases, or conditions associated with insufficient neuronal differentiation and / or with elevated LPA levels in neural tissues.

The present invention relates to a pharmaceutical composition for treatment and / or prevention for urinary diseases comprising a lysophosphatidic acid (LPA) receptor regulator.As LPA receptor regulators act on urethra and prostate, compounds acting on this receptor are useful in treating urinary diseases (urinary incontinence, dysuria, etc.). For example, an LPA receptor agonist useful for treatment of urinary incontinence, while an LPA receptor antagonist is useful for treatment of dysuria, ischuria, pollakiuria, nocturia, urodynia and benign prostatic hyperplasia.

Phosphatidic acid is administered orally to increase muscle mass and strength in exercising mammals. Phosphatidic acid is administered orally to aging, bedridden or cachectic patients to improve nitrogen balance. The preferred form of phosphatidic acid for administration is phosphatidic acid-enriched lecithin. Creatine is co-administered orally to increase the muscle-building and strength effect. Other suggested additives include nutritional and herbal supplements, micronutrients and hormones.

The invention discloses a method for finishing fabric through plant essential oil thermosensitive liposomes. The method comprises the following steps: mixing and stirring tea tree essential oil, menthol and artemisia vulgaris oil to obtain a natural fragrant antibacterial agent; dissolving the natural fragrant antibacterial agent in a phosphate buffered solution; mixing natural phosphatide, phosphatidylcholine, glyceryl phosphatide, phosphatidyl ethanolamine, phosphatidylserine and phosphatidic acid, adding cholesterol, dissolving the mixture into chloroform, pouring into a container, and evaporating at the room temperature until a layer of uniform thin film is formed on the container wall; adding the phosphate buffered solution of the natural fragrant antibacterial agent into the container coated with the thin film in ultrasonic water bath, and performing ultrasonic oscillation to obtain a thermosensitive liposome suspension liquor; adding an adhesive into the thermosensitive liposome suspension liquor, and stirring at the room temperature until the adhesive agent is completely dissolved, so as to obtain a thermosensitive fragrant antibacterial finishing agent; immersing and rolling fabric into the finishing liquid, immersing and rolling for the second time, and finally finishing and shaping the fabric by adopting a freezing and drying method.

Pharmaceutical composition for regulation of pancreatic juice secretion characterized by comprising a lisophosphatidic acid (LPA) receptor modulator. Since an LPA receptor modulator has an effect of regulating the secretion of pancreatic juice, a compound acting on this receptor is useful in treating diseases in association with disorders in pancreatic juice secretion. For example, an LPA receptor agonist is useful in treating and / or preventing pancreatic diseases and obesity, while an LPA receptor antagonist is useful in treating and / or preventing maldigestion, constipation, diarrhea and cibophobia.

The invention relates to a method for preparing phosphatidyserine. The method for preparing phosphatidyserine comprises the following steps of mixing phosphatidylcholine or natural phospholipid containing phosphatidylcholine with tween-80, L-serine, calcium chloride, buffer solution and phospholipase D, and stirring and reacting the above materials at 35-45 DEG C for 8-10h; separating out the crude products from reaction and floating, carrying out centrifugal separation on the aqueous phase and crude products, washing the crude products subjected to separation and carrying out centrifugal filtration; adding the crude products subjected to centrifugal filtration into absolute ethyl alcohol for immersing, stirring, and carrying out centrifugal filtration; and carrying out vacuum drying on the products subjected to centrifugal filtration to obtain the phosphatidyserine. The invention aims to provide a new method for preparing phosphatidyserine to solve the problems that in the prior art, the byproduct of phosphatidic acid is large in amount, the conversion rate is unsatisfactory and the product cost is high.

The present invention relates to a method for identifying therapeutic agents for reducing and monitoring the growth, erosion, rupture or stability of an atherosclerotic plaque comprising the analysis of the differential expression of at least two genes coding proteins chosen among among Stearoyl CoA desaturase, Phosphatidic acid phosphate, and Phosphoinositide-specific-phospholipase-B1, eventually in association with the analysis of the differential expression of at least one gene coding a protein choosen in the group comprising Aldose reductase and aldehyde reductase, Sphingomyelinase, Acid ceramidase, Ceramide glucosyl transferase, Sphingosin phosphate liase, Thymosine beta 4, Aldehyde dehydogenase, ATPase Ca++ binding protein and CD163.

The invention discloses an oxaliplatin liposome, a preparation method and application thereof. The oxaliplatin liposome contains oxaliplatin, phospholipid and cholesterol, wherein, based on the total weight of the phospholipid, the phospholipid comprises the following components in percentage by weight: 75 to 90 percent of phosphatidylcholine (PC), and 10 to 25 percent of phosphatidyl glycerol (PG) and phosphatidic acid (PA); the weight ratio of the oxaliplatin to the phospholipid is 1:3-20, and the weight ratio of the cholesterol to the phospholipid is 1:2-10.

This invention relates to plant LPAATs, means to identify such proteins, amino acid and nucleic acid sequences associated with such protein, and methods to obtain, make and / or use such plant LPAATs. Purification, especially the removal of plant membranes and the substantial separation away from other plant proteins, and use of the plant LPAAT is provided, including the use of the protein as a tool in gene isolation for biotechnological applications. In addition, nucleic acid sequences encoding LPAAT protein regions are provided, and uses of such sequences for isolation of LPAAT genes from plants are considered.

In the present invention, cDNA microarrays to investigate pituitary gene expression in two chicken lines that were selected for low and high body fat (Lean and Fat). Differentially expressed genes between lines are potential candidates as genetic markers for high and low potential for body fat accumulation. The lysophosphatidic acid (LPA) receptor-1 (LPAR1) was identified as a potential marker, being differentially expressed between the lean and fat lines at the early ages. The invention provides SNPs that can introduce a GATA site in the promoter of LPAR1 which can upregulate its expression in the lean chickens, and increased LPA signaling and which can inhibit preadipocyte differentiation. Conversely, SNPs are provided that cause loss of the GATA binding site and cause decreased levels of LPAR1 expression and attenuated inhibition of adipocyte maturation in fat chickens.

Recombinant microbial cells are disclosed herein that produce an oil comprising at least 28 percent eicosapentaenoic acid (EPA) measured as a weight percent of dry cell weight. These cells may comprise a polynucleotide sequence encoding an active acyl-CoA:lysophosphatidylcholine acyltransferase (LPCAT) comprising at least one amino acid mutation in a membrane-bound O-acyltransferase motif. In addition, the cells may comprise a down-regulation of an endogenous polynucleotide sequence encoding Sou2 sorbitol utilization protein, and / or one or more polynucleotides encoding phospholipid:diacylglycerol acyltransferase (PDAT), delta-12 desaturase, a dihomo-gamma-linolenic acid (DGLA) synthase multizyme, delta-8 desaturase, malonyl-CoA synthetase (MCS), or acyl-CoA:lysophosphatidic acid acyltransferase (LPAAT). Also disclosed are methods of using the recombinant microbial cells to produce oil containing omega-3 polyunsaturated fatty acids such as EPA.

It is intended to provide a vector for delivering a target substance into a nucleus or a cell. This object is achieved by providing a vector for delivering a target substance into a nucleus or a cell which comprises a lipid membrane structure having a lipid membrane containing an anionic lipid such as phosphatidic acid, cardiolipin, etc.

The invention discloses a method for preparing phosphatidylserine. According to the method, phospholipid and L-serine are subjected to phospholipid translating acylation reaction under the action of phospholipase D to generate the phosphatidylserine, wherein the phospholipid translating acylation reaction is carried out in a homogeneous medium system and the yield of the phosphatidylserine reaches 80-98 percent. The method disclosed by the invention has the advantages that due to the adoption of a green reaction medium, a reaction system is a homogeneous medium system. No phosphatidic acid as a byproduct is generated, high catalytic efficiency of enzyme and favorable quality of products are obtained and the process is safe and environment-friendly.

The invention relates to oligoarginine modified phospholipid, nanoparticles assembled by the oligoarginine modified phospholipid, a preparation method of the oligoarginine modified phospholipid and an application of the nanoparticles. After oligoarginine peptide chains are activated by DCC (dicyclohexylcarbodiimide) / NHS (N-hydroxysuccinimide), the oligoarginine peptide chains react with phosphatidyl ethanolamine, purification is performed, and oligoarginine modified phosphatidyl ethanolamine is obtained; or the oligoarginine peptide chains react with DCC / NHS activated phosphatidic acid, and oligoarginine modified phosphatidic acid is obtained through purification; or the oligoarginine peptide chains react with nitrophenyl chloroformate activated phosphatidylcholine, and oligoarginine modified phosphatidylcholine is obtained through purification. The nanoparticles assembled by the oligoarginine modified phospholipid is used for supporting genes, small-interfering RNA, polypeptides or proteinic drugs, antibodies and chemical drugs, and the formed aqueous dispersion of the drug-carrying nanoparticles is used for delivering drugs for in-vitro cells or in-vivo local intravenous injection. The nanoparticles are effectively promoted to enter the cells, and the intracellular drug delivery efficiency is improved.

Compositions and methods for making and using humanized anti-LPA monoclonal antibodies, and fragments and derivatives thereof, are described.

Disclosed is a lipid preparation comprising a glycerophospholipid or salt, conjugate and derivatives thereof, particularly phosphatidylserine (PS), phosphatidylcholine (PC), phosphatidylethanolamine (PE), phosphatidyl-inositol (PI), phosphatidylglycerol (PG) and phosphatidic acid (PA), and poly-unsaturated fatty acid (PUFA) acyl groups, particularly long-chain poly-unsaturated fatty acid (LC-PUFA) acyl groups such as omega-3 and / or omega-6 acyl groups, wherein said PUFA is covalently bound to said glycerophospholipid. The disclosed preparations possess an improved bioactivity, and are useful in the treatment of various cognitive and mental conditions and disorders and for maintenance of normal functions of brain-related systems and processes, for example ADHD.

PCT No. PCT / IL97 / 00147 Sec. 371 Date Feb. 24, 1999 Sec. 102(e) Date Feb. 24, 1999 PCT Filed May 6, 1997 PCT Pub. No. WO97 / 41874 PCT Pub. Date Nov. 13, 1997The invention is to a method for the treatment of withdrawal symptoms selected from the group consisting of nausea, sweating, shaking, substance craving and hot flushes.

Pathogenic effector proteins which include one or more RxLR, dEER, Pexel or analogous motifs are blocked from entry into plant or animal cells by binding one or more of the motifs with a blocking compound which prevents binding of phosphoinositides or other polar lipids to the motifs which is a prerequisite for translocation of the pathogenic effector proteins into the plant or animal cell. The blocking compounds can take a variety of forms including synthetic peptides or the hydrophilic head-groups of phosphoinositides, phosphatidic acids, phospholipids, or sphingolipids. Suitable blocking compounds can be identified by assays demonstrating binding to RxLR, dEER, Pexel or analogous motifs. In addition, pathogenic effector proteins can be identified by analyzing whether they contain structural RxLR motifs using hidden markov modeling.

Multi-phase release compositions, methods of using the compositions, and methods for manufacturing the compositions are provided. Multi-phase release compositions include ingredients useful in sports nutrition including ingredients useful in muscle building, energy output and weight loss. Sports nutrition ingredients are designed for immediate and extended release dependent on the particular sport nutrition motivated use. One sports nutrition ingredient that can be utilized in either or both the immediate release phase or the extended release phase is phosphatidic acid.

The invention relates to the technical field of drink processing, in particular to a passion fruit drink and a preparation method thereof. The passion fruit drink is mainly prepared from passion fruits, pitaya, wax apples, endive, Jerusalem artichoke, purple lotus fruits, dark green tea, twisted-flower rush herb, phosphatidic acid, mannan, chitosan, lactobacillus fermenti, lactobacillus acidophilus, bacillus licheniformis, bifidobacterium, saccharomycetes, lactosucrose, isomaltooligosaccharide, stachyose, complex enzyme and other raw materials through raw material treatment, enzymolysis, enzyme deactivation, blending, sterilization and other steps. The raw material formula of the drink is the most scientific and reasonable, the drink has uniform color, has no precipitates, has a fragrant and strong fruit flavor, tastes mellow, refreshing, sour, sweet and delicious, has a long shelf life, has effectively increased soluble solid content, has high nutritional value, can effectively promote intestinal tract movement, has the effects of clearing heat, removing toxins, producing saliva, slaking thirst, clearing intestines, maintaining beauty and keeping young and is a functional healthcare drink capable of regulating intestinal florae and invigorating intestines and stomach, and the preparation process is simple and easy to operate.

The invention belongs to the technical field of medicine, and particularly relates to a carboxylic acid derivative as a lysophosphatidic acid receptor antagonist as shown in a general formula (I) and a pharmaceutically acceptable salt thereof or an stereomer thereof, wherein A, B, C, D, E, R1, R3, R4, R5, RA, RB, RC, m and p are as defined in the specification. The invention also relates to preparation methods of the compounds, a drug composition or a drug preparation which contains the compounds and an important application of the compounds in preparing a drug for treating and / or preventing LPA-dependence or LPA-mediation diseases.

The invention discloses a metal cut cooling antirust solution, and belongs to the technical field of metal machining cooling protection. The metal cut cooling antirust solution comprises the following ingredients in parts by weight: 10-20 parts of oleic acid, 10-30 parts of phosphaticdic acid, 5-10 parts of triethanolamine, 0.2-1 part of absolute ethyl alcohol, 1-5 parts of antirust agent, 15-25 parts of emulsifier, 0.8-2 parts of dodecenylsuccinic acid, and 0.03-0.5 part of organic silicon defoamer. The metal cut cooling antirust solution is reasonable in formula, and has excellent lubrication, antirust, cooling, cleaning and germicidal activity properties; the metal cut cooling antirust solution is low in volatility, high in biodegradability, recyclable, capable of being used as a universal metal cutting fluid instead of mineral oil-based metal machining liquid, and is superior to the ordinary mineral oil-based machining liquid in machining property and the environment-friendliness property; the metal cut cooling antirust solution is non-toxic and odorless, has no irritation to the skin of operating personnel and harmless to a human body.

The invention discloses a method for preparing an omega-3 fatty acid-rich phospholipid from algal oil. The method comprises 1) acquiring algal oil, 2) separating algal oil phospholipid through addingfood grade acetone into the algae oil, carrying out full mixing for 45-60min, carrying out centrifugation at 4000-5000 rpm / min for 15-20 min to obtain precipitates which are crude algal oil phospholipid and repeating the above processes, 3) purifying phosphatidylcholine through eluting a chromatographic column through ethanol for a silica gel chromatographic column to separate and remove phosphatidylethanolamine, phosphatidylserine, phosphatidylinositol and phosphatidic acid and then separating and collecting phosphatidylcholine through elution of the chromatographic column with ethanol, and 4) synthesizing omega-3 fatty acid-rich phospholipid through mixing the extracted crude algal oil phospholipid or phosphatidylcholine and ethanol, adding lipase and an appropriate amount of water intothe mixture and preparing the omega-3 fatty acid-rich phospholipid through the lipase alcoholysis reaction. When the phosphatidylcholine is used as a synthesizing raw material, the total content of the omega-3 fatty acid after the enzyme catalytic reaction can reach to 70% or more.

Fluorogenic lysophosphatidic acid derivatives which can be used as substrates in a continuous, fluorogenic assay that can be performed in microtiter plates. The assays permit measuring LysoPLD activity levels in normal events such as pregnancy or disease states such as cancer. In addition, the present invention can be adopted to high throughout screening(HTS) for identification of potential inhibitors of lysoPLD activity.

The invention discloses cubilose toner and a manufacturing method thereof. Denatonium Benzoate, butanediol, trehalose, propylene glycol, glycerinum, ethyl alcohol, hydroxyethyl cellulose, polydimethylsiloxane, potassium sorbate, sorbic acid, ethylhexylglycerin, hyaluronic acid, polyethylene glycol-8, glycerin grape glycosides, ascorbic acid phosphatidic acid and a solvent are put into a container, heated to the temperature of 90 DEG C, stirred and dissolved; heat preservation is conducted for 15 min, and then cooling is conducted till the temperature is 42 DEG C; apus affinis cubilose extracts, beer saccharomycete extracts, hydrolyzed pearls and essence are added, and stirring is conducted for 3-10 min; citric acid is added for adjusting the pH; and standing is conducted for defoaming, cooling is conducted to the normal temperature, and filling is conducted so that finished products can be obtained. The apus affinis cubilose extracts, the beer saccharomycete extracts, the hydrolyzed pearls and the like are added, the irritation is low, a good skin care effect for moisturizing and nourishing the skin can be achieved, and the skin can be promoted to absorb the cubilose toner better.